B7‐H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer
Open Access
- 2 April 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 131 (11), 2528-2536
- https://doi.org/10.1002/ijc.27566
Abstract
In colorectal cancer there is a need for molecular markers that can complement the histopathological staging in predicting the likelihood of disease recurrence following curatively intended surgery. B7-H3 is an immunoregulatory protein shown to be overexpressed in several cancer forms, often associated with more advanced disease and poor prognosis. We wanted to examine whether B7-H3 could be a potential prognostic marker in colorectal cancer. Paraffin-embedded samples from 277 colorectal cancer patients were immunostained with anti-B7-H3 antibody. B7-H3 was expressed in the tumor cell cytoplasm and cell membrane in 62% and 46% of the samples, respectively. Unexpectedly, B7-H3 was expressed in the nucleus in 30% of the tumors. The nuclear localization was confirmed by Western immunoblotting of subcellular fractions. Importantly, in colon cancer, nuclear B7-H3 expression was independently and significantly associated with reduced metastasis-free, disease-specific and overall survival. B7-H3 expression in tumor-associated vasculature and fibroblasts was observed in the majority of samples, and endothelial B7-H3 expression was also significantly associated with poor outcome in colon cancer. In rectal cancer patients, the only significant association was between fibroblast B7-H3 expression and shorter metastasis-free survival. Few significant associations to clinicopathological parameters were seen. The results indicate that nuclear B7-H3 might be involved in colon cancer progression and metastasis, and suggest that nuclear B7-H3 could become a useful prognostic marker in colon cancer.Keywords
This publication has 47 references indexed in Scilit:
- High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patientsClinical & Experimental Metastasis, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasLaboratory Investigation, 2010
- Nuclear trafficking of the epidermal growth factor receptor family membrane proteinsOncogene, 2010
- T-cell Co-regulatory Molecule Expression in Renal Angiomyolipoma and Pulmonary LymphangioleiomyomatosisUrology, 2009
- Clinical importance of B7-H3 expression in human pancreatic cancerBritish Journal of Cancer, 2009
- B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interactionEuropean Journal of Immunology, 2009
- Trafficking of receptor tyrosine kinases to the nucleusExperimental Cell Research, 2009
- Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responsesProceedings of the National Academy of Sciences of the United States of America, 2008
- B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcomeProceedings of the National Academy of Sciences of the United States of America, 2007